Biotica Technology Ltd.
Founded1996
HeadquartersCambridge, UK
Key people
Peter F Leadlay (Founder)
Number of employees
15-30

Biotica Technology ltd., was a biotech company which focused on optimised polyketide therapeutics for high-value indications.[1] Following successful partnerships with leading pharmaceutical companies including Wyeth and GSK, the company was eventually dissolved on the 12th September 2015.[2] It was estimated that about £15 million had been invested in the business.[3]

Their technology platform was based on manipulation of the microbial genetics, using techniques such as mutasynthesis,[4] to make improved analogues of natural product polyketides [5] [6] in a similar way to Kosan Biosciences.[7] This eventually led to a successful patent appeal at the EPO.[8]

Sanglifehrins

Sanglifehrin is a mixed polyketide / non-ribosomal peptide natural product found to be a potent cyclophilin inhibitor and antiviral. Biotica had been developing analogues of this for Hepatitis C in 2011, in particular BC556[9] and the sangamides.[10] BC556 and the sangamides were acquired by Neurovive, a Swedish mitochondrial medicine company in 2013.[11]

Rapamycins

Biotica discovered and developed analogues of rapamycin, a potent polyketide mTOR inhibitor, which were eventually licensed to Wyeth in 2006 in a deal worth up to $195 million.[12] Following acquisition of Wyeth by Pfizer, these rapalogs were reacquired by Biotica in 2011.[13]

Erythromycins

Biotica discovered and developed analogues of the polyketide antibiotic erythromycin for use in inflammatory diseases, which were licensed to GSK in 2009 in a deal worth up to £89 million.[14]

Administration and sale of assets

Following entering administration in 2012, the assets of Biotica were eventually sold for a total of £500K[15] to companies including the Swedish Pharmaceutical company Neurovive[16] and the British biotech Isomerase Therapeutics.[17]

References

  1. ↑ "Biotica Technology Linkedin page". LinkedIn. 23 March 2005. Retrieved 6 September 2023.
  2. ↑ "BIOTICA TECHNOLOGY LIMITED overview". find-and-update.company-information.service.gov.uk. Retrieved 6 September 2023.
  3. ↑ "Biotica goes into administration". McTear Williams & Wood Limited. Retrieved 6 September 2023.
  4. ↑ Weissman, Kira J. (2007). "Mutasynthesis – uniting chemistry and genetics for drug discovery". Trends in Biotechnology. Cell Press. 25 (4): 139–142. doi:10.1016/j.tibtech.2007.02.004. PMID 17306390.
  5. ↑ Moss, David S.; Jelaska, Sibila; Pongor, Sándor (2005). "Essays in Bioinformatics". NATO Science Series, I: Life and Behavioural Sciences. IOS Press. 368: 185. ISBN 978-1-58603-539-6.
  6. ↑ "Discovering Drugs from Bugs". The Naked Scientists. 20 July 2008. Retrieved 27 September 2023.
  7. ↑ Gullo, Vincent P.; Hughes, Dallas E. (2005). "Exploiting new approaches for natural product drug discovery in the biotechnology industry". Drug Discovery Today: Technologies. Elsevier. 2 (3): 281–286. doi:10.1016/j.ddtec.2005.08.002. PMID 24981948.
  8. ↑ "Biotica Technology Limited Wins Landmark European Patent Appeal". BioSpace. Retrieved 6 September 2023.
  9. ↑ "Biotica nominates drug candidate, BC556, a cyclophilin inhibitor to treat Hepatitis C". www.businesswire.com. 31 October 2011. Retrieved 6 September 2023.
  10. ↑ "EP Vantage Interview - Biotica heads to clinic with new hep C drug". Evaluate.com. 2 November 2011. Retrieved 6 September 2023.
  11. ↑ "NeuroVive: NeuroVive acquires highly potent, novel cyclophilin inhibitors from Biotica – Abliva". abliva.com. 11 March 2013. Retrieved 6 September 2023.
  12. ↑ "Biotica inks $195M licensing deal with Wyeth |". Fierce Biotech. Retrieved 6 September 2023.
  13. ↑ "Biotica Regains Worldwide Rights to Its Rapamycin Analogue Program |". Fierce Biotech. Retrieved 6 September 2023.
  14. ↑ "Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline;". Fierce Biotech. Retrieved 27 September 2023.
  15. ↑ "Creditors to gain from Cambridge biotech sales". McTear Williams and Wood. Retrieved 27 September 2023.
  16. ↑ "Sweden's Neurovive acquires assets from UK's Biotica". Wall Street Journal. Retrieved 27 September 2023.
  17. ↑ "Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline;". Isomerase.com. 9 December 2014. Retrieved 27 September 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.